{"id":"W2954103814","doi":"10.1016/j.jval.2019.04.025","title":"CP2 ESTIMATING THE SURVIVAL AND COST IMPACT OF INTRODUCING FIRST-LINE ALECTINIB AND OSIMERTINIB FOR PATIENTS WITH ADVANCED NSCLC: AN ITEN MODEL ASSESSMENT","year":2019,"lang":"en","type":"article","venue":"Value in Health","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Alectinib; Osimertinib; Medicine; Oncology; Lung cancer; Internal medicine; Erlotinib; Crizotinib; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005014082,0.001489585,0.001588125,0.0009603945,0.0004500045,0.002126802,0.001974529,0.002595846,0.009269992],"category_scores_gemma":[0.01523916,0.000919336,0.002779036,0.0008744706,0.0005840317,0.001234018,0.001165045,0.002784959,0.0005633375],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003030264,"about_ca_system_score_gemma":0.004375395,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.06229748,"about_ca_topic_score_gemma":0.03289764,"domain_scores_codex":[0.9988804,0.0006588525,0.00002929827,0.0001571518,0.0000892337,0.0001850886],"domain_scores_gemma":[0.9861466,0.01204179,0.0005147296,0.0002653231,0.0006813436,0.0003500889],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.0003976897,0.0001145224,0.003193196,0.00008213369,0.0001639801,0.00005329617,0.0000123186,0.9869984,0.00008279863,0.002108694,0.001422717,0.005370332],"study_design_scores_gemma":[0.0001096187,0.000139566,0.0008894073,0.00001582844,0.00008430969,0.00002163753,0.00001956252,0.996491,0.00007902076,0.001744657,0.0003965177,0.000008709499],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7978995,0.002281112,0.1400994,0.008989668,0.0004147611,0.0008303288,0.01380994,0.0007502597,0.034925],"genre_scores_gemma":[0.9675647,0.0003884709,0.01521264,0.0004766318,0.0001032376,0.0003463782,0.003277869,0.00007915618,0.01255091],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06229748,"threshold_uncertainty_score":0.1238698,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04173580079861362,"score_gpt":0.3126661928145402,"score_spread":0.2709303920159266,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}